Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
15 oct. 2024 08h00 HE | Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
OncIcons_Winner_1080x1080-1-OncIcons_Winner_1080x1080
Targeted Oncology™ announces Eric Cheung, D.O., as the second recipient of the 2024 Oncology Icons award
10 oct. 2024 09h00 HE | Targeted Oncology™
CRANBURY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
Immuneering-logo (1).png
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
06 août 2024 16h05 HE | Immuneering Corporation
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering-logo (1).png
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
31 juil. 2024 16h05 HE | Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
Immuneering-logo (1).png
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
07 mai 2024 16h05 HE | Immuneering Corporation
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering-logo (1).png
Immuneering Recognizes Melanoma Awareness Month
06 mai 2024 16h30 HE | Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
OncIcons_Winner_1080x1080 (1)
Targeted Oncology™ announces first recipient of 2024 for its Oncology Icons award program
23 avr. 2024 10h46 HE | Targeted Oncology™
CRANBURY, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
Immuneering-logo (1).png
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
09 avr. 2024 12h00 HE | Immuneering Corporation
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Immuneering-logo (1).png
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
27 mars 2024 08h00 HE | Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Immuneering-logo (1).png
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
14 mars 2024 07h00 HE | Immuneering Corporation
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for...